NVCR NovoCure Ltd
Nasdaq · SEC CIK 1645113 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $3.25M 20 sales by 14 insiders
- Filings on record
- 265 since 2021-07-08, latest 2026-07-01 16:33
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| Paravasthu Mukund | COO | — | $693.8K |
| Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| Brackmann Christoph | CFO | — | $85.3K |
| Stafford Kristin | Dir | — | $46.4K |
| Ocean Allyson J | Dir | — | $46.4K |
| Scannell Timothy J | Dir | — | $46.4K |
| VERNON W ANTHONY | Dir | — | $46.4K |
| Hung David | Dir | — | $46.4K |
Transactions 293
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 16:33 | 2026-06-30 | NVCR | Puri Michal Nath | CHRO | A - Grant | $11.15 | +1,905 | 203.2K | +0.9% | +$21.2K | |
| 2026-07-01 16:30 | 2026-06-30 | NVCR | Leonard Frank X | CEO | A - Grant | $11.15 | +1,905 | 461.4K | +0.4% | +$21.2K | |
| 2026-07-01 16:30 | 2026-06-30 | NVCR | Ben Arye Barak | GC | A - Grant | $11.15 | +1,299 | 243.8K | +0.5% | +$14.5K | |
| 2026-07-01 16:30 | 2026-06-30 | NVCR | Danziger Asaf | Dir | A - Grant | $11.15 | +268 | 416.7K | +0.1% | +$2,988 | |
| 2026-06-05 16:28 | 2026-06-04 | NVCR | Leonard Frank X | CEO | S - Sale | $17.93 | -34.3K | 459.5K | -7% | -$614.6K | |
| D | 2026-06-05 16:27 | 2026-06-03 | NVCR | LEUNG GABRIEL | Dir | A - Grant | $0.00 | +11.6K | 101.1K | +13% | $0 |
| D | 2026-06-05 16:27 | 2026-06-03 | NVCR | Stafford Kristin | Dir | A - Grant | $0.00 | +11.6K | 22.9K | +103% | $0 |
| D | 2026-06-05 16:27 | 2026-06-03 | NVCR | Ocean Allyson J | Dir | A - Grant | $0.00 | +11.6K | 22.9K | +103% | $0 |
| D | 2026-06-05 16:26 | 2026-06-03 | NVCR | Scannell Timothy J | Dir | A - Grant | $0.00 | +11.6K | 25.9K | +81% | $0 |
| D | 2026-06-05 16:26 | 2026-06-03 | NVCR | HILLEMAN JERYL L | Dir | A - Grant | $0.00 | +11.6K | 25.5K | +84% | $0 |
| D | 2026-06-05 16:26 | 2026-06-03 | NVCR | Hung David | Dir | A - Grant | $0.00 | +11.6K | 32.1K | +57% | $0 |
| D | 2026-06-05 16:26 | 2026-06-03 | NVCR | Madden Martin J. | Dir | A - Grant | $0.00 | +11.6K | 30.3K | +62% | $0 |
| D | 2026-06-05 16:25 | 2026-06-03 | NVCR | VERNON W ANTHONY | Dir | A - Grant | $0.00 | +11.6K | 209.3K | +6% | $0 |
| 2026-06-03 16:54 | 2026-06-02 | NVCR | LEUNG GABRIEL | Dir | S - Sale | $15.77 | -2,945 | 89.5K | -3% | -$46.4K | |
| 2026-06-03 16:53 | 2026-06-02 | NVCR | Stafford Kristin | Dir | S - Sale | $15.77 | -2,945 | 11.3K | -21% | -$46.4K | |
| 2026-06-03 16:53 | 2026-06-02 | NVCR | Ocean Allyson J | Dir | S - Sale | $15.77 | -2,945 | 11.3K | -21% | -$46.4K | |
| 2026-06-03 16:53 | 2026-06-02 | NVCR | Scannell Timothy J | Dir | S - Sale | $15.77 | -2,945 | 14.3K | -17% | -$46.4K | |
| 2026-06-03 16:53 | 2026-06-02 | NVCR | HILLEMAN JERYL L | Dir | S - Sale | $15.77 | -2,945 | 13.9K | -18% | -$46.4K | |
| 2026-06-03 16:52 | 2026-06-02 | NVCR | VERNON W ANTHONY | Dir | S - Sale | $15.77 | -2,945 | 197.7K | -1% | -$46.4K | |
| 2026-06-03 16:52 | 2026-06-02 | NVCR | Hung David | Dir | S - Sale | $15.77 | -2,945 | 20.5K | -13% | -$46.4K | |
| D | 2026-04-28 16:27 | 2026-04-28 | NVCR | VERNON W ANTHONY | Dir | M - OptEx | $11.39 | +21.5K | 200.6K | +12% | +$244.9K |
| D | 2026-03-05 | 2026-03-03 | NVCR | Weinberg Uri | Chf Medical, Innovation Ofr | A - Grant | $0.00 | +50.1K | 273.6K | +22% | $0 |
| D | 2026-03-05 | 2026-03-04 | NVCR | Weinberg Uri | Chf Medical, Innovation Ofr | S - Sale | $13.31 | -6,412 | 267.2K | -2% | -$85.3K |
| 2026-03-05 | 2026-03-04 | NVCR | Leupin Nicolas | Former Chief Medical Off | S - Sale | $13.31 | -1,100 | 103.0K | -1% | -$14.6K | |
| D | 2026-03-05 | 2026-03-03 | NVCR | Puri Michal Nath | CHRO | A - Grant | $0.00 | +40.1K | 202.4K | +25% | $0 |
| D | 2026-03-05 | 2026-03-04 | NVCR | Puri Michal Nath | CHRO | S - Sale | $13.31 | -1,100 | 201.3K | -0.5% | -$14.6K |
| D | 2026-03-05 | 2026-03-04 | NVCR | Brackmann Christoph | CFO | S - Sale | $13.31 | -6,412 | 182.8K | -3% | -$85.3K |
| D | 2026-03-05 | 2026-03-03 | NVCR | Brackmann Christoph | CFO | A - Grant | $0.00 | +55.1K | 189.3K | +41% | $0 |
| DM | 2026-03-05 | 2026-03-03 | NVCR | DOYLE WILLIAM F | Executive COB, Dir | A - Grant | $0.00 | +400.3K | 200.0K | New | $0 |
| DM | 2026-03-05 | 2026-03-03 | NVCR | DOYLE WILLIAM F | Executive COB, Dir | S - Sale | $12.98 | -71.9K | 349.7K | -17% | -$933.1K |
| 2026-03-05 | 2026-03-04 | NVCR | Cordova Ashley | Former CEO | F - Tax | $13.30 | -17.6K | 422.6K | -4% | -$234.6K | |
| D | 2026-03-05 | 2026-03-03 | NVCR | Paravasthu Mukund | COO | A - Grant | $0.00 | +45.1K | 121.5K | +59% | $0 |
| DM | 2026-03-05 | 2026-03-04+ | NVCR | Paravasthu Mukund | COO | S - Sale | $13.72 | -48.6K | 116.1K | -30% | -$667.1K |
| D | 2026-03-05 | 2026-03-04 | NVCR | Leonard Frank X | CEO | S - Sale | $13.31 | -5,607 | 493.8K | -1% | -$74.6K |
| D | 2026-03-05 | 2026-03-03 | NVCR | Leonard Frank X | CEO | A - Grant | $0.00 | +150.0K | 499.4K | +43% | $0 |
| D | 2026-03-05 | 2026-03-03 | NVCR | Ben Arye Barak | GC | A - Grant | $0.00 | +50.1K | 242.5K | +26% | $0 |
| 2026-03-03 | 2026-02-27 | NVCR | Puri Michal Nath | CHRO | S - Sale | $13.66 | -1,441 | 162.3K | -0.9% | -$19.7K | |
| 2026-03-03 | 2026-02-28 | NVCR | Ben Arye Barak | GC | A - Grant | $0.00 | +17.8K | 192.3K | +10% | $0 | |
| 2026-03-03 | 2026-02-28 | NVCR | Leonard Frank X | CEO | A - Grant | $0.00 | +18.6K | 356.6K | +6% | $0 | |
| M | 2026-03-03 | 2026-02-27+ | NVCR | Leonard Frank X | CEO | S - Sale | $13.59 | -17.0K | 349.4K | -5% | -$230.5K |
| 2026-03-03 | 2026-02-27 | NVCR | Leupin Nicolas | Former Chief Medical Off | S - Sale | $13.66 | -1,029 | 104.1K | -1.0% | -$14.1K | |
| 2026-03-03 | 2026-02-28 | NVCR | Cordova Ashley | Former CEO | A - Grant | $0.00 | +23.8K | 449.8K | +6% | $0 | |
| M | 2026-03-03 | 2026-02-27+ | NVCR | Cordova Ashley | Former CEO | F - Tax | $13.71 | -21.2K | 426.0K | -5% | -$290.4K |
| M | 2026-03-03 | 2026-02-27+ | NVCR | Paravasthu Mukund | COO | S - Sale | $13.62 | -1,963 | 76.3K | -3% | -$26.7K |
| 2026-03-03 | 2026-02-28 | NVCR | Weinberg Uri | Chf Medical, Innovation Ofr | A - Grant | $0.00 | +13.0K | 226.7K | +6% | $0 | |
| M | 2026-03-03 | 2026-02-27+ | NVCR | Weinberg Uri | Chf Medical, Innovation Ofr | S - Sale | $13.68 | -10.7K | 213.8K | -5% | -$146.9K |
| 2026-01-12 | 2026-01-11 | NVCR | Paravasthu Mukund | COO | F - Tax | $14.35 | -2,133 | 78.3K | -3% | -$30.6K | |
| 2025-11-04 | 2025-11-01 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | F - Tax | $12.81 | -966 | 347.7K | -0.3% | -$12.4K | |
| 2025-11-04 | 2025-10-31 | NVCR | Puri Michal Nath | CHRO | F - Tax | $12.82 | -752 | 163.8K | -0.5% | -$9,641 | |
| M | 2025-11-04 | 2025-11-01+ | NVCR | Paravasthu Mukund | COO | F - Tax | $12.26 | -3,117 | 80.4K | -4% | -$38.2K |
| 2025-11-04 | 2025-11-04 | NVCR | Brackmann Christoph | CFO | F - Tax | $12.23 | -7,033 | 134.1K | -5% | -$86.0K | |
| 2025-09-08 | 2025-09-05 | NVCR | Cordova Ashley | CEO | P - Purchase | $12.22 | +81.5K | 437.6K | +23% | +$996.5K | |
| M | 2025-07-30 | 2025-07-29 | NVCR | Brackmann Christoph | CFO | P - Purchase | $11.59 | +20.0K | 136.2K | +17% | +$231.8K |
| 2025-07-01 | 2025-06-30 | NVCR | Danziger Asaf | Dir | A - Grant | $15.13 | +833 | 416.5K | +0.2% | +$12.6K | |
| 2025-07-01 | 2025-06-30 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $15.13 | +833 | 348.7K | +0.2% | +$12.6K | |
| 2025-07-01 | 2025-06-30 | NVCR | Puri Michal Nath | CHRO | A - Grant | $15.13 | +833 | 164.5K | +0.5% | +$12.6K | |
| 2025-07-01 | 2025-06-30 | NVCR | Ben Arye Barak | GC | A - Grant | $15.13 | +769 | 174.5K | +0.4% | +$11.6K | |
| 2025-07-01 | 2025-06-30 | NVCR | Cordova Ashley | CEO | A - Grant | $15.13 | +833 | 356.0K | +0.2% | +$12.6K | |
| 2025-06-06 | 2025-06-04 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $0.00 | +179.4K | 347.9K | +107% | $0 | |
| D | 2025-06-06 | 2025-06-04 | NVCR | VERNON W ANTHONY | Dir | A - Grant | $0.00 | +11.2K | 179.1K | +7% | $0 |
| D | 2025-06-06 | 2025-06-04 | NVCR | Stafford Kristin | Dir | A - Grant | $0.00 | +11.2K | 14.3K | +367% | $0 |
| D | 2025-06-06 | 2025-06-04 | NVCR | Ocean Allyson J | Dir | A - Grant | $0.00 | +11.2K | 14.3K | +367% | $0 |
| D | 2025-06-06 | 2025-06-04 | NVCR | Scannell Timothy J | Dir | A - Grant | $0.00 | +11.2K | 17.2K | +186% | $0 |
| D | 2025-06-06 | 2025-06-04 | NVCR | Hung David | Dir | A - Grant | $0.00 | +11.2K | 23.4K | +92% | $0 |
| D | 2025-06-06 | 2025-06-04 | NVCR | HILLEMAN JERYL L | Dir | A - Grant | $0.00 | +11.2K | 16.8K | +201% | $0 |
| D | 2025-06-06 | 2025-06-04 | NVCR | LEUNG GABRIEL | Dir | A - Grant | $0.00 | +11.2K | 92.4K | +14% | $0 |
| 2025-06-04 | 2025-06-03 | NVCR | LEUNG GABRIEL | Dir | S - Sale | $17.31 | -999 | 81.2K | -1% | -$17.3K | |
| 2025-06-04 | 2025-06-03 | NVCR | Stafford Kristin | Dir | S - Sale | $17.28 | -999 | 3,054 | -25% | -$17.3K | |
| MT | 2025-06-04 | 2025-06-02 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $17.50 | -30.2K | 168.5K | -15% | -$528.4K |
| 2025-06-04 | 2025-06-03 | NVCR | HILLEMAN JERYL L | Dir | S - Sale | $17.26 | -999 | 5,591 | -15% | -$17.2K | |
| 2025-06-04 | 2025-06-03 | NVCR | Ocean Allyson J | Dir | S - Sale | $17.29 | -999 | 3,054 | -25% | -$17.3K | |
| 2025-06-04 | 2025-06-03 | NVCR | VERNON W ANTHONY | Dir | S - Sale | $17.35 | -999 | 167.9K | -0.6% | -$17.3K | |
| 2025-06-04 | 2025-06-03 | NVCR | Madden Martin J. | Dir | S - Sale | $17.19 | -999 | 18.7K | -5% | -$17.2K | |
| 2025-06-04 | 2025-06-03 | NVCR | Hung David | Dir | S - Sale | $17.30 | -999 | 12.2K | -8% | -$17.3K | |
| 2025-06-04 | 2025-06-03 | NVCR | Scannell Timothy J | Dir | S - Sale | $17.32 | -999 | 6,018 | -14% | -$17.3K | |
| 2025-05-05 | 2025-05-03 | NVCR | Paravasthu Mukund | COO | S - Sale | $17.91 | -592 | 83.6K | -0.7% | -$10.6K | |
| D | 2025-03-06 | 2025-03-04 | NVCR | Leupin Nicolas | Chief Medical Off | A - Grant | $18.19 | +55.0K | 105.1K | +110% | +$1000.0K |
| D | 2025-03-06 | 2025-03-04 | NVCR | Cordova Ashley | CEO | A - Grant | $18.19 | +151.2K | 355.2K | +74% | +$2.75M |
| D | 2025-03-06 | 2025-03-04 | NVCR | Weinberg Uri | Chief Innovation Off | A - Grant | $18.19 | +55.0K | 221.2K | +33% | +$1000.0K |
| D | 2025-03-06 | 2025-03-04 | NVCR | Ben Arye Barak | GC | A - Grant | $18.19 | +55.0K | 173.7K | +46% | +$1000.0K |
| D | 2025-03-06 | 2025-03-04 | NVCR | Paravasthu Mukund | COO | A - Grant | $18.19 | +55.0K | 84.1K | +188% | +$1000.0K |
| D | 2025-03-06 | 2025-03-04 | NVCR | Puri Michal Nath | CHRO | A - Grant | $18.19 | +55.0K | 163.7K | +51% | +$1000.0K |
| D | 2025-03-06 | 2025-03-04 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $18.19 | +55.0K | 198.6K | +38% | +$1000.0K |
| D | 2025-03-06 | 2025-03-04 | NVCR | Brackmann Christoph | CFO | A - Grant | $18.19 | +55.0K | 121.2K | +83% | +$1000.0K |
| 2025-03-04 | 2025-03-03 | NVCR | Cordova Ashley | CEO | S - Sale | $18.54 | -2,053 | 204.0K | -1.0% | -$38.1K | |
| 2025-03-04 | 2025-03-03 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $18.54 | -2,527 | 143.7K | -2% | -$46.9K | |
| 2025-03-04 | 2025-03-03 | NVCR | Paravasthu Mukund | COO | S - Sale | $18.54 | -250 | 29.2K | -0.8% | -$4,635 | |
| 2025-03-04 | 2025-03-03 | NVCR | Weinberg Uri | Chief Innovation Off | S - Sale | $18.92 | -268 | 166.2K | -0.2% | -$5,071 | |
| MA | 2025-03-03 | 2025-02-28 | NVCR | Weinberg Uri | Chief Innovation Off | S - Sale | $18.75 | -4,637 | 166.8K | -3% | -$86.9K |
| M | 2025-03-03 | 2025-02-28 | NVCR | Weinberg Uri | Chief Innovation Off | S - Sale | $18.75 | -4,637 | 166.8K | -3% | -$86.9K |
| M | 2025-03-03 | 2025-02-27+ | NVCR | Cordova Ashley | CEO | S - Sale | $19.72 | -13.5K | 210.2K | -6% | -$266.1K |
| MA | 2025-03-03 | 2025-02-27+ | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $19.70 | -15.0K | 149.0K | -9% | -$296.2K |
| M | 2025-03-03 | 2025-02-27+ | NVCR | Paravasthu Mukund | COO | S - Sale | $19.70 | -2,014 | 30.1K | -6% | -$39.7K |
| MA | 2025-03-03 | 2025-02-27 | NVCR | Leupin Nicolas | Chief Medical Off | S - Sale | $20.02 | -991 | 50.3K | -2% | -$19.8K |
| MA | 2025-03-03 | 2025-02-27+ | NVCR | Paravasthu Mukund | COO | S - Sale | $19.70 | -2,014 | 29.8K | -6% | -$39.7K |
| MA | 2025-03-03 | 2025-02-27 | NVCR | Puri Michal Nath | CHRO | S - Sale | $20.02 | -1,387 | 108.9K | -1% | -$27.8K |
| M | 2025-03-03 | 2025-02-27 | NVCR | Leupin Nicolas | Chief Medical Off | S - Sale | $20.02 | -991 | 50.1K | -2% | -$19.8K |
| MA | 2025-03-03 | 2025-02-27+ | NVCR | Cordova Ashley | CEO | S - Sale | $19.72 | -13.5K | 206.1K | -6% | -$266.1K |
| M | 2025-03-03 | 2025-02-27+ | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $19.70 | -15.0K | 149.0K | -9% | -$296.2K |
| M | 2025-03-03 | 2025-02-27 | NVCR | Puri Michal Nath | CHRO | S - Sale | $20.02 | -1,387 | 108.9K | -1% | -$27.8K |
Purchase Sale Sale after option exercise All abbreviations